Holly K. Koblish

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Xiangdong Liu, Niu Shin, Holly K. Koblish et al. · Blood · 2010 · 559 citations · Full text

Medicine, Immunology, Oncology +14

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

Stefani Spranger, Holly K. Koblish, Brendan Horton et al. · Journal for ImmunoTherapy of Cancer · 2014 · 545 citations · Full text

Life Sciences, Immunology, Oncology +17

Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells

Bruce Grasberger, Tianbao Lu, Carsten J. Schubert et al. · Journal of Medicinal Chemistry · 2005 · 427 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

Eddy W. Yue, Richard Sparks, Padmaja Polam et al. · ACS Medicinal Chemistry Letters · 2017 · 296 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +8

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

Xiangdong Liu, Qian Wang, Gengjie Yang et al. · Clinical Cancer Research · 2011 · 274 citations

Medicine, Oncology, Pharmacology +16